Title | Finding Nivo: A Case Report of 2 Forms of Nivolumab-Induced Liver Injury in an Allograft Liver in the Immediate Post-Transplant Period. |
Publication Type | Journal Article |
Year of Publication | 2022 |
Authors | Tow CY, Castrodad-RodrÃguez CA, Panarelli N, Massoumi H |
Journal | Transplant Proc |
Volume | 54 |
Issue | 10 |
Pagination | 2794-2796 |
Date Published | 2022 Dec |
ISSN | 1873-2623 |
Keywords | Allografts, Chemical and Drug Induced Liver Injury, Chronic, Graft Rejection, Humans, Liver Neoplasms, Nivolumab |
Abstract | Recent reports have emerged regarding the utilization of checkpoint inhibitors for downstaging hepatocellular carcinoma before liver transplantation. Early post-transplant acute cellular rejection has rarely led to graft loss. We report the first case of 2 forms of nivolumab-associated liver injury on biopsy of the allograft organ in a single patient who received nivolumab for cancer downstaging before liver transplantation: 1. mild acute cellular rejection according to Risk Analysis Index scoring and 2. zone 3 inflammation and apoptosis consistent with a more classic drug-induced liver injury pattern. This case not only adds further evidence about the risk for rejection post-transplant, but sheds light on other injuries checkpoint inhibitors can cause to the allograft. |
DOI | 10.1016/j.transproceed.2022.07.018 |
Alternate Journal | Transplant Proc |
PubMed ID | 36319498 |
Related Faculty:
Nicole Panarelli, M.D.